Please use this identifier to cite or link to this item: 10.55563/clinexprheumatol/d2qz38
Title: The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases : insights after the first 5 years of the ERN ReCONNET
Authors: ERN ReCONNET
Talarico, R.
Aguilera, S.
Alexander, T.
Bulina, I.
Dāvidsone, Z.
Mosca, Marta
Department of Paediatrics
Keywords: connective tissue diseases;European Commission;European Reference Networks;patient care;rare and complex diseases;rheumatic and musculoskeletal diseases;3.1 Basic medicine;3.3 Health sciences;1.1. Scientific article indexed in Web of Science and/or Scopus database;Rheumatology;Immunology and Allergy;Immunology
Issue Date: 1-May-2022
Citation: ERN ReCONNET , Talarico , R , Aguilera , S , Alexander , T , Bulina , I , Dāvidsone , Z & Mosca , M 2022 , ' The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases : insights after the first 5 years of the ERN ReCONNET ' , Clinical and Experimental Rheumatology , vol. 40 , no. 5, S134 , pp. S3-S11 . https://doi.org/10.55563/clinexprheumatol/d2qz38
Abstract: In order to address the main challenges related to the rare diseases (RDs) the European Commission launched the European Reference Networks (ERNs), virtual networks involving healthcare providers (HCPs) across Europe. The mission of the ERNs is to tackle low prevalence and RDs that require highly specialised treatment and a concentration of knowledge and resources. In fact, ERNs offer the potential to give patients and healthcare professionals across the EU access to the best expertise and timely exchange of lifesaving knowledge, trying to make the knowledge travelling more than patients. For this reason, ERNs were established as concrete European infrastructures, and this is particularly crucial in the framework of rare and complex diseases in which no country alone has the whole knowledge and capacity to treat all types of patients. It has been five years since their kick-off launch in Vilnius in 2017. The 24 ERNs have been intensively working on different transversal areas, including patient management, education, clinical practice guidelines, patients' care pathways and many other fundamental topics. The present work is therefore aimed not only at reporting a summary of the main activities and milestones reached so far, but also at celebrating the first 5 years of the ERN on Rare and Complex Connective Tissue and Musculo-skeletal Diseases (ReCONNET), in which the members of the network built together one of the 24 infrastructures that are hopefully going to change the scenario of rare diseases across the EU.
Description: Funding Information: I. Bulina has received honoraria from Abbvie, Boehringer Ingelheim, Janssen and Pfizer. N. Costedoat-Chalumeau has received grants from UCB for a clinical research study. M. Matucci-Ce rinic has received grants from Janssen and MSD, and he is a member of speak ers bureau for Janssen, Sandoz, Bio gen, BI, Lilly and MSD. A. Meyer re ceived honoraria (<10,000 euros) from Lilly, LFB, Pfizer, Boehringer, Sanofi and research grants/support from CSL Behring, LFB, Sanofi, Fresenius Kabi and BMS. L. Mouthon received a grant from LFB. J.M. van Laar has received honoraria from Abbvie, Boehringer In-gelheim, Celltrion, Galapagos, Magenta, Roche, and grants from Astra Zeneca, Boehringer Ingelheim, Roche and Thermofischer. J.K. de Vries-Bouwstra received consulting fees from Abbvie, Janssen and Boehringer Ingelheim, and research grants from Roche, Galapagos and Janssen. The other authors have declared no competing interests. Publisher Copyright: © Copyright CliniCal and ExpErimEntal rhEumatology 2022.
DOI: 10.55563/clinexprheumatol/d2qz38
ISSN: 0392-856X
Appears in Collections:Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.